China Blood Products Industry Report, 2009
  • Oct/2009
  • Hard Copy
  • USD $1,100
  • Pages:42
  • Single User License
    (PDF Unprintable)       
  • USD $1,200
  • Code: ZN006
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,300
      

The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China’s blood products has soared up and corporate profitability also has increased significantly.

China's blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy.

China’s Plasma Collection, 2001-2010E
 2009101303.gif
Source: ResearchInChina

The report makes an in-depth analysis of the status quo of China’s blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China’s seven key blood product companies, such as Hualan Biological Engineering Inc.

As a key company of blood products R&D and production in China, the revenue of Hualan Biological Engineering Inc achieved RMB475 million in 2008, up 35.32% year-on-year; and the total profit was RMB218 million, a 69.73% YoY rise. Moreover, the current and newly-built plasma collection stations primarily distribute in Guizhou, Guangxi and Chongqing. Up to 2008, it had owned 11 plasma collection stations, and three under construction. It has eased the short supply of plasma via building new plasma collection stations.

Hualan Biological Engineering has taken the lead in blood products field in China, in the meantime, it has accessed into vaccine sector actively. It was the first to obtain Influenza A strain on Jun 8, 2009, and it entered the clinical trials on July 22. The monthly output capacity of Influenza A vaccine can reach 7.5 million units, and it would carry the reserves of 4 million units before Sep 15. Besides, it had produced 13 million units of Influenza A vaccine before Oct 1. As is estimated, it can supply 35-40 million units of Influenza A vaccine by the end of 2009.

Prime Operating Revenue of Hualan Biological Engineering Inc, 2007-2011E
 2009101304.gif
Source: ResearchInChina

1 China’s Blood Products Industry
1.1 Market  
1.1.1 Profile
1.1.2 Industry Characteristics 
1.2 Competitive Patterns
1.3 Existing Problems
1.4 Development Trend 
  
2. China’s Plasma Market
2.1 Plasma Collection Station 
2.2 Plasma Volume 
2.3 Plasma Price
2.4 Difficulties in Industry Development 
2.5 Development Trend 

3. Global Blood Products Industry
3.1 Development Courses
3.2 Status Quo 
3.3 Comparison between China and International Blood Products Industry Development 
 
4. Key Blood Products
4.1 HSA
4.2 IVIG
4.3 HBIG
4.4 Rabies Immunoglobulin
4.5 Tetanus Immunoglobulin  
4.6 Coagulation Factor FVIII 

5. Key Manufacturers in China 
5.1 Overall Analysis
5.2 Hualan Biological Engineering Ltd
5.2.1 Profile
5.2.2 Operation
5.2.3 Development Trend 
5.3 Shanghai RAAS Blood Products Co., Ltd
5.3.1 Profile
5.3.2 Operation
5.3.3 Development Trend
5.4 CNBG Shanghai Institute of Biological Products
5.4.1 Profile
5.4.2 Operation
5.5 Beijing Tiantan Biological Products Co., Ltd 
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Trend
5.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
5.6.1 Profile
5.6.2 Operation
5.7 Guiyang Qianfeng Biological Product Liability Co., Ltd.

6. Investment  
6.1 Opportunities 
6.2 Risks
6.3 Suggestions   
Varieties, Applications and Manufacturers of China’s Main Blood Products 
Management Modes of Plasma Collection Station before System-Reform 
Blood Product Industry Chain after System-Reform 
State’s Laws & Regulations on Blood Products Industry
Plasma Volume Trend of China’s Blood Products, 2003-2011
China’s Plasma Collection Volume Trend, 2001-2010 
Comparison between China’s and International Blood Product Market Structure, 2008 
China’s HSA Output, 2005-2008 
China’s HSA Prices, 2003-2010 
China’s IVIG Output, 2003-2008 
China’s IVIG Prices, 2003-2010 
Concentration Trend of Companies in the Future
Plasma Collection Capability of Hualan Biological Engineering’s Current and Would-be Plasma Collection Stations  
Revenue/Cost Structure of Hualan Biological Engineering, 2008 
Main Business Revenues of Hualan Biological Engineering, 2007-2011 
Profitability of Hualan Biological Engineering, 2008-2011 
The Number of Hualan Biological Engineering’s Plasma Collection Stations, 2008 
China’s Flu Vaccine Market Share, 2008 
Shanghai RAAS Revenue/Profit Ratio by Business, 2008 
Shanghai RAAS Revenue/Gross Profit Structure, 2008 
Shanghai RAAS Product Price Trend, 2005-2011 
Shanghai RAAS Projects Invested by Fund-Raising, 2008 
Output Capacity Comparison of Shanghai RAAS Fund-Raising Investment Projects before and after Completion, 2008  
The List of SIBP Products
Revenue Trend of Beijing Tiantan Biological, 2008-2011 
Beijing Tiantan Biological Revenue Change before and after Acquisition of Chengdu Rongsheng 
Products List of Guiyang Qianfeng
China’s HSA Provisional Maximum Retail Price, 2008

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号